Javascript must be enabled to continue!
Kallikrein‐binding protein is induced by growth hormone in the dwarf rat
View through CrossRef
ABSTRACT
Rat kallikrein‐binding protein (KBP), a member of the serpin family, is a tissue kallikrein inhibitor. It has been shown to be a potential pathogenic factor of diabetic retinopathy and may play a role in animal development and growth. To determine whether reduced KBP expression is involved in retarded animal growth, we examined the
in vivo
effect of growth hormone (GH) deficiency on the expression of KBP in the Lewis dwarf (
dw/dw
). We found that serum levels of functionally active KBP were reduced in the dwarf rat (
P
<0.05) as determined by complex formation assay between serum KBP and
125
I‐labeled rat tissue kallikrein. Enzyme‐linked immunosorbent assay showed that KBP levels were significantly reduced in the serum of the dwarf rat compared to the Lewis rat (213.8 ng/ml vs. 413.8 ng/ml,
n
=4,
P
<0.01). The decreased KBP levels were confirmed by Western blot analysis. Moreover, treatment of the dwarf rat with recombinant human GH for 4 wk resulted in a significant increase in KBP activity (
P
<0.01) and serum KBP levels compared with the untreated dwarf rat (549.8 ng/ml,
n
=5, vs. 213.8 ng/ml,
n
=4,
P
<0.02). Northern blot analysis and densitometry showed that liver KBP mRNA levels were reduced by fivefold in the dwarf rat compared to the Lewis rat and the decrease was reversed by the GH treatment. These results indicate that the KBP levels are regulated at the RNA level. Furthermore,
in vitro
studies using cultured rat hepatocytes showed that GH may have a direct regulatory effect on KBP expression since KBP levels increased in the conditioned media of cells treated with GH. These results demonstrated that KBP is reduced in the genetic dwarf rat and is restored to normal by GH; therefore, KBP is a GH‐dependent protein and may be a new target for studying the mechanism of pathological animal growth.—Hatcher, H. C., Wright, N. M., Chao, J., Chao, L., Ma, J.‐x. Kallikrein binding protein is induced by growth hormone in the dwarf rat.
FASEB J
. 13, 1839–1844 (1999)
Title: Kallikrein‐binding protein is induced by growth hormone in the dwarf rat
Description:
ABSTRACT
Rat kallikrein‐binding protein (KBP), a member of the serpin family, is a tissue kallikrein inhibitor.
It has been shown to be a potential pathogenic factor of diabetic retinopathy and may play a role in animal development and growth.
To determine whether reduced KBP expression is involved in retarded animal growth, we examined the
in vivo
effect of growth hormone (GH) deficiency on the expression of KBP in the Lewis dwarf (
dw/dw
).
We found that serum levels of functionally active KBP were reduced in the dwarf rat (
P
<0.
05) as determined by complex formation assay between serum KBP and
125
I‐labeled rat tissue kallikrein.
Enzyme‐linked immunosorbent assay showed that KBP levels were significantly reduced in the serum of the dwarf rat compared to the Lewis rat (213.
8 ng/ml vs.
413.
8 ng/ml,
n
=4,
P
<0.
01).
The decreased KBP levels were confirmed by Western blot analysis.
Moreover, treatment of the dwarf rat with recombinant human GH for 4 wk resulted in a significant increase in KBP activity (
P
<0.
01) and serum KBP levels compared with the untreated dwarf rat (549.
8 ng/ml,
n
=5, vs.
213.
8 ng/ml,
n
=4,
P
<0.
02).
Northern blot analysis and densitometry showed that liver KBP mRNA levels were reduced by fivefold in the dwarf rat compared to the Lewis rat and the decrease was reversed by the GH treatment.
These results indicate that the KBP levels are regulated at the RNA level.
Furthermore,
in vitro
studies using cultured rat hepatocytes showed that GH may have a direct regulatory effect on KBP expression since KBP levels increased in the conditioned media of cells treated with GH.
These results demonstrated that KBP is reduced in the genetic dwarf rat and is restored to normal by GH; therefore, KBP is a GH‐dependent protein and may be a new target for studying the mechanism of pathological animal growth.
—Hatcher, H.
C.
, Wright, N.
M.
, Chao, J.
, Chao, L.
, Ma, J.
‐x.
Kallikrein binding protein is induced by growth hormone in the dwarf rat.
FASEB J
.
13, 1839–1844 (1999).
Related Results
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Expression and characterization of rat kallikrein-binding protein in Escherichia coli
Rat kallikrein-binding protein is a novel serine-proteinase inhibitor that forms a covalent complex with tissue kallikrein. We have purified rat kallikrein-binding protein and clon...
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats
In DOCA-salt hypertension, renal kallikrein levels are increased and may play a protective role in renal injury. We investigated the effect of enhanced kallikrein levels on kidney ...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...
Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation
Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation
Tissue kallikrein exerts various biological functions through kinin formation with subsequent kinin B2 receptor activation. Recent studies showed that tissue kallikrein directly ac...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
14th Annual Meeting, December 1980, Canberra1. Effect of dexamethasone on pineal β‐adrenoceptors. C. A. Maxwell, A. Foldes, N. T. Hinks and R. M. Hoskinson2. A clinicopathological ...
Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis
Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis
Kallikrein/kinin has been shown to protect against ischemia/reperfusion-induced myocardial infarction and apoptosis. In the present study, we examined the potential neuroprotective...
Human tissue kallikrein induces hypotension in transgenic mice.
Human tissue kallikrein induces hypotension in transgenic mice.
We investigated the role of the kallikrein-kinin system in blood pressure control by developing transgenic mice overexpressing human tissue kallikrein. Two lines of transgenic mice...
Kallikrein Gene Delivery Improves Serum Glucose and Lipid Profiles and Cardiac Function in Streptozotocin-Induced Diabetic Rats
Kallikrein Gene Delivery Improves Serum Glucose and Lipid Profiles and Cardiac Function in Streptozotocin-Induced Diabetic Rats
We investigated the role of the kallikrein-kinin system in cardiac function and glucose utilization in the streptozotocin (STZ)-induced diabetic rat model using a gene transfer app...

